EUVIMEDEUVIMED entdecken
Crossref

Tandem‐Activatable PROTAC Prodrug for Tumor Biomarker‐Driven Near‐Infrared Opto‐Proteolysis

Xiaoyan Lu, Xiaoning Wang, Hanwen Liao, Baitong Sha, Yan Zhang, Jinbo Li iD

Angewandte Chemie International Edition · 25.08.2025 · 64 (35)

DOI: 10.1002/anie.202510641 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 09.07.2025. Verfasst von Xiaoyan Lu und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Analytical Chemistry for Life Sciences, Jiangsu Key Laboratory of Advanced Organic Materials, School of Chemistry and Chemica…. Hauptthemen laut MEDLINE: Prodrugs, Photosensitizing Agents, Biomarkers, Tumor, Antineoplastic Agents. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor‐specific protein degradation is crucial for successful cancer treatment by proteolysis‐targeting chimera (PROTAC), which however still remains challenging. Here, we report a tandem‐activatable PROTAC prodrug (TAP) strategy for precise on‐tumor proteolysis in vivo. TAP is constructed by caging PROTAC with a tumor‐homing cyclopeptide through a tandem‐locking linker, which comprises a singlet‐oxygen ( 1 O 2 ) cleavable moiety, a near‐infrared (NIR) photosensitizer (PS) and a Cathepsin B (CatB)‐cleavable dipeptide substrate. The proteolytic activity of TAP is initially turned off but can be sequentially switched on by tumor biomarker enzyme CatB and NIR light. Such a tandem‐lock design ensures that PROTAC exclusively degrade oncoprotein target in tumor. The results revealed that TAP carried out a tumor‐selective degradation of bromodomain‐containing protein 4 (BRD4) under the cooperative action by CatB and NIR light, which further synergized with photodynamic therapy (PDT) by the PS to suppress tumor growth. This work thus presents the first tandem‐activatable approach for spatiotemporally controlled proteolysis to minimize the off‐tumor toxicity of PROTAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsPhotosensitizing AgentsBiomarkers, TumorAntineoplastic AgentsHumansProteolysisInfrared RaysPhotochemotherapyCathepsin BAnimalsMiceNeoplasmsCell Line, TumorMolecular StructureDrug Screening Assays, Antitumor

Stichwörter der Autor:innen

Cancer treatmentNear‐infrared photoactivationPROTACTandem‐lockingTumor biomarker

Substanzen

ProdrugsPhotosensitizing AgentsBiomarkers, TumorCathepsin BAntineoplastic Agents

Autor:innen und Institutionen

  • State Key Laboratory of Analytical Chemistry for Life Sciences, Jiangsu Key Laboratory of Advanced Organic Materials, School of Chemistry and Chemical Engineering, Chemistry and Biomedicine Innovation Center (ChemBIC),…

ORCID-Profile: Jinbo Li

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Jiangsu Province

Zitieren

APA

Lu, X., Wang, X., Liao, H., Sha, B., Zhang, Y., & Li, J. (2025). Tandem‐Activatable PROTAC Prodrug for Tumor Biomarker‐Driven Near‐Infrared Opto‐Proteolysis. Angewandte Chemie International Edition, 64(35). https://doi.org/10.1002/anie.202510641

Vancouver

Lu X, Wang X, Liao H, Sha B, Zhang Y, Li J. Tandem‐Activatable PROTAC Prodrug for Tumor Biomarker‐Driven Near‐Infrared Opto‐Proteolysis. Angewandte Chemie International Edition. 2025;64(35). doi:10.1002/anie.202510641

BibTeX
@article{Lu2025,
  author = {Lu, Xiaoyan and Wang, Xiaoning and Liao, Hanwen and Sha, Baitong and Zhang, Yan and Li, Jinbo},
  title = {Tandem‐Activatable PROTAC Prodrug for Tumor Biomarker‐Driven Near‐Infrared Opto‐Proteolysis},
  journal = {Angewandte Chemie International Edition},
  year = {2025},
  volume = {64},
  number = {35},
  doi = {10.1002/anie.202510641}
}
Kostenlos starten →